A Pilot Study of Adherence to Oral Anticancer Treatment Using Electronic Monitoring System
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cancer
- Sponsor
- Centre Jean Perrin
- Enrollment
- 33
- Locations
- 1
- Primary Endpoint
- evaluation of adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor.
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
The purpose of this study is to describe adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor. Moreover, this study is aimed at evaluating the feasibility to use a " Medication Event Monitoring System " (MEMS®) in order to assess adherence of an oral anticancer treatment delivered by dispensary pharmacy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \> 18 years
- •histologically proven malignant tumor
- •documented decision of treatment with i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor
- •ambulatory treated subject
- •Subject who accept to use MEMS monitors to automatically compile their drug dosing histories
- •Written informed consent
Exclusion Criteria
- •any severe concomitant wich makes it undesirable for the patient to participate in the study or which would jeopardize adherence with trial protocol
- •patient who does not agreed to participate the program
Outcomes
Primary Outcomes
evaluation of adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor.
Time Frame: everey visit during 6 months
Secondary Outcomes
- evaluation of liberal nurse satisfaction(inclusion)
- resort to healthcare system (oncologist, doctor, nurse, hospital pharmacy, dispensary pharmacy)(during 6 months)
- Patient satisfaction(6 months)
- drug interaction(during 6 months)